PARP1 and small cell lung carcinoma: Our results have provided a comprehensive profile of HRR gene mutations in Chinese SCLC, illuminated the relationships of HRR gene mutation patterns with TMB and PD‐L1 and summarized the proportion of SCLC patients who might benefit from PARP inhibitors, ICIs or their combination.